Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 15 of the 29 sources its claims cite were checked for support.
Abstract
SagA promotes immunotherapy response: The gut microbiome can influence the treatment outcome for cancer patients receiving PD-L1 immunotherapy, but the mechanisms underlying favorable responses are unclear. Griffin et al . found that a particular type of bacteria called enterococci enhance anti–PD-L1 immunotherapy in mice (see the Perspective by Ansaldo and Belkaid). The researchers show that enterococci secrete an enzyme called SagA that breaks down components of the bacterial cell wall. This process results in the release of muramyl peptide fragments, which in turn act as stimulatory molecules to promote signaling of the innate immune sensor protein NOD2 and improved immunotherapy responses. —PNK
Overview
CoChat Summary
TL;DR
Enterococcus species that produce secreted NlpC/p60 peptidoglycan hydrolases (SagA orthologs) improve checkpoint inhibitor responses in mouse tumor models by generating NOD2-active muropeptides. Engineering SagA into non-active E. faecalis or probiotic L. lactis, or giving synthetic MDP-l,d, reproduced antitumor benefit with anti-PD-L1.
Key findings
- In antibiotic-pretreated C57BL/6 mice bearing B16-F10 melanoma, oral E. faecium Com15 plus anti-PD-L1 reduced tumor size at high and low antibody doses versus anti-PD-L1 alone; all three E. faecium isolates tested were active, while no E. faecalis strain was. Similar fecal CFU across strains indicated the effect was not due to bacterial load.
- Active species E. durans, E. hirae, and E. mundtii shared peptidoglycan remodeling signatures and SagA orthologs; C-terminal NlpC/p60 domains were >90% identical, E. gallinarum’s closest protein was 67% identical, and E. faecalis lacked direct orthologs. Recombinant orthologs showed d,l-endopeptidase activity producing GMDP.
- E. faecalis engineered to express SagA plus anti-PD-L1 reduced B16-F10 growth, and this required NOD2. L. lactis expressing wild-type SagA matched E. faecium benefit, whereas catalytically inactive C443A SagA did not.
- Synthetic NOD2-active MDP-l,d with anti-PD-L1 significantly inhibited tumors, unlike MDP-l,l; scRNA-seq showed more intratumoral T lymphocytes, cytotoxic gene enrichment, a Cx3cr1/Nr4a1 monocyte increase, and NF-κB/inflammatory signatures.
Methods
- Mouse tumor models: SPF C57BL/6 mice (Jackson) pretreated two weeks with ampicillin, colistin, and streptomycin, then orally supplemented with enterococci, implanted with B16-F10 melanoma and treated with anti-PD-L1; separate Taconic SPF mice without antibiotics; MCA205 fibrosarcoma with anti-PD-1 and MC38 colorectal carcinoma with anti-CTLA-4; B16-OVA for flow cytometry.
- Bacterial and biochemical assays: HPLC-MS peptidoglycan fragment profiling, genomic/sequence alignments for SagA orthologs, Western blot for secretion, recombinant hydrolase activity assays, fecal/tissue CFU, and 16S rRNA microbiome analysis.
- Immune profiling: tumor-infiltrating lymphocytes quantified by flow cytometry; CD45+ tumor cells from MDP stereoisomer-treated mice analyzed by scRNA-seq and gene set enrichment.
Limitations
- Stated: the authors could not detect SagA orthologs in clinical metagenomic datasets before checkpoint blockade, which they attribute to low E. faecium genome coverage (9.34%). They also note uncertainty for the secretion-deficient L. lactis SagA strain, suggesting either low secreted SagA was sufficient or non-secreted SagA leaked via lysis.
- Evident: efficacy and mechanism data come from mouse tumor models and bacterial/muropeptide interventions, not human clinical trials; antibiotic pretreatment substantially depletes resident microbiota, although a non-antibiotic SPF model was also used.
- Evident: microbiome analyses showed incomplete antibiotic clearance and shifts over time, and some differential OTUs appeared in only one cage per condition, limiting microbiome attribution.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 7 Not checked · 63 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple analyses of the commensal microbiome from human cohorts treated with immunotherapies targeting PD-1 have revealed that the bacterial genus Enterococcus is enriched in responding patients (12, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the paper’s results (our copy labels the section Abstract; page unavailable), Enterococcus faecium is listed among species more abundant in responders. The paper reports enrichment of that species in a metastatic melanoma cohort, not enrichment of the genus Enterococcus as a whole across human cohorts. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, the gut microbiota has emerged as a potent new factor associated with the efficacy of anti–CTLA4, anti–PD-1, and anti–PD-L1 treatment (8-14).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Partly supportedcites [8] Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther P-L, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350, 1079– 1084 (2015). 26541610 PMC4721659 sourceExperimental — accuracy not yet measured
The Abstract reports that gut microbiota composition influences the efficacy of CTLA-4 blockade, supporting the anti-CTLA-4 part of the sentence. The passages in our copy do not establish the same association for anti-PD-1 or anti-PD-L1 treatment, so this source does not support the full three-treatment claim. (LLM, conf=0.88)
- Partly supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 sourceExperimental — accuracy not yet measured
The supplied passages report that gut microbial composition influenced response to anti–PD-L1 treatment in mice. They discuss effects on the PD-1/PD-L1 axis more broadly, but do not report a direct anti–PD-1 treatment test; the CTLA-4 passage says the principles *could* apply to that pathway. Thus this source supports the anti–PD-L1 part, but not the claim that microbiota is established as associated with efficacy for all three treatments. (LLM, conf=0.88)
- Supportedcites [10] Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY, Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 19, 848– 855 (2017). 28923537 PMC5602478 source
The Introduction reports that gut microbiota influence responses to anti-PD-L1 and anti-CTLA4 therapy in mouse models. The Discussion reports gut microbial species associated with clinical response to anti-PD1 alone and combined anti-PD1/anti-CTLA4 therapy in melanoma patients. Together, these passages support the broad association claimed; page numbers are not provided in our copy. (LLM, conf=0.92)
- Supportedcites [11] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza I source
The paper reports an association between gut microbiome composition and anti-PD-1 response in melanoma patients, cites a similar finding in a small anti-CTLA-4 cohort, and reports improved anti-PD-L1 response in mice receiving fecal transplants from anti-PD-1 responders. These passages support the broad association claimed, although the evidence comes from different populations and study designs. (LLM, conf=0.87)
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
The paper reports an association between gut microbiota and anti–PD-1 response in metastatic melanoma patients, and its mouse experiments show differing anti–PD-L1 efficacy by microbiota (Abstract; Fig. 3F discussion; page unavailable). It included four anti–CTLA-4 recipients but reports no separate microbiota–efficacy association for that treatment. The anti–PD-L1 result is in mice, not patients. (LLM, conf=0.88)
- Supportedcites [14] Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, Weber JS, Osman I, Ahn J, Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019). 31597568 PMC6785875 source
The Background reports gut-microbiota effects on anti-CTLA-4 and anti-PD-L1 immunotherapy in mice and an association with clinical response in human melanoma patients. The Discussion describes associations with response to anti-PD-1 and anti-CTLA-4 treatment in melanoma patients. Together, these passages support the broad association attributed to this source. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“consistent with enhanced priming of a tumor antigen-specific immune response (9, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 source
The paper reports greater expansion of tumor-antigen-specific CD8+ T cells in tumor-draining lymph nodes and describes differences in T-cell priming in vivo (passages [1] and [2], page unavailable). This supports the cited interpretation that an increase in antigen-specific CD8+ T cells is consistent with enhanced priming. The paper studied SIY-specific cells; the citing paper’s OVA-specific observation is not itself attributed to this source. (LLM, conf=0.88)
- Supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 source
The passage describing the mouse tumor experiment reports more SIY-specific CD8+ T cells and explicitly interprets this as increased priming of tumor antigen-specific CD8+ T cells. The citation is attached to that interpretation, not to the citing study’s OVA-specific measurement. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Significant enrichment of hallmark gene sets (33) for inflammatory response and NF-κB signaling were found in the MDP-l,d dataset (Table S8).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [33] Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P, The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417– 425 (2015). 26771021 PMC4707969 source
The citation (33) is attached to 'hallmark gene sets' — an identification of the resource the citing authors ran enrichment against — not to their own MDP-l,d result. Our copy is exactly that source: the DISCUSSION states the hallmarks are released as the H Collection in MSigDB v5.0, every set name starting with HALLMARK, with Table 1 listing all 50 hallmarks and their descriptions; the RESULTS (Analysis of necrosis in glioblastoma) treat NFκB signaling as one of the biological themes covered, and the protein-phenotype validation section documents the immune/inflammatory hallmarks (IL6 JAK STAT3, IL2 STAT5 signaling). No passage of our copy reports anything about an 'MDP-l,d' dataset, which is consistent with that being the citing authors' own analysis rather than something attributed here. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We further confirmed that SagA orthologs are found in humans through alignment of the SagA NlpC/p60 domain with genomes within the Human Microbiome Project (24) (Fig. 2C, Table S5).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [24] Consortium THMJRS, A catalog of reference genomes from the human microbiome. Science. 328, 994– 999 (2010). 20489017 PMC2940224 source
The citation identifies the Human Microbiome Project genomes used for the citing authors’ alignment; the SagA result is presented as the citing authors’ own finding. The source’s Reference genome progress section describes the HMP-sequenced genomes, and its Data release section says their sequences and annotations were made available. (LLM, conf=0.91)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
54 more claims
Create a free account to see all 78 claims and to verify the 14 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, cause-effect relationships between the prevalence or relative abundance of particular taxa, and clinical regression or progression, have been shown in animal models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several probiotics or their products can inhibit tumor development by suppressing inflammation and promoting anti-tumor immune responses6,7.”
From Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Enterococcus expressed and secreted orthologs NlpC/p60 PG hydrolase SagA and could promote expression of the innate immune sensor protein nucleotide-binding oligomerization domain containing 2 (NOD2) and augment ICI antitumor efficacy [109] (Fig. 5F).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [109]
In the citing paper
“Thus, the peptidoglycan hydrolase SagA from Enterococcus faecium can be transferred into Lactococcus lactis to generate a probiotic strain that stimulates innate immune responses via NOD2 activation and promotes ICI antitumor activity in mice.26”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies
Nguyen, L.-T., Schmidt, H. A., von Haeseler, A., & Minh, B. Q. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msu300 · Cited by 26,046
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Cited by
Items 301–367 of 367
Adamson, C., Ng, E. W. L., Ng, A. W. R., Feng, S., & Qiao, Y. (2025) · JACS Au · doi:10.1021/jacsau.5c00790 · Cited by 3
Non-invasive Fluorescence Imaging of Gut Commensal Bacteria in Live MicePreprint
Apostolos, A. J., Chordia, M. D., Kolli, S. H., Rutkowski, M. R., & Pires, M. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.05.489569 · Cited by 1
Klupt, S., Fam, K. T., Zhang, X., Chodisetti, P. K., Mehmood, A., Boyd, T., Grotjahn, D. A., Park, D., & Hang, H. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.19.567738 · Cited by 1
Self-citationKlupt, S., Fam, K. T., Zhang, X., Chodisetti, P. K., Mehmood, A., Boyd, T., Grotjahn, D. A., Park, D., & Hang, H. C. (2024) · eLife · doi:10.7554/elife.95297.1 · Cited by 1
Self-citationKlupt, S., Fam, K. T., Zhang, X., Chodisetti, P. K., Mehmood, A., Boyd, T., Grotjahn, D. A., Park, D., & Hang, H. C. (2024) · eLife · doi:10.7554/elife.95297.2 · Cited by 2
Self-citationBirla, P., Yang, L., Shan, W., Minamisawa, S., Dhaygude, O., Manoj, H. P., Zheng, Y., Fan, H., Beauregard, H. E., Smith, K. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690539 · Cited by 1
Trang, K., Gulick, D. A., Truell, J. C., Tian, J., Bodkhe, R., Hiseni, P., Gravdal, K., Kirubakaran, T. G., Casèn, C., Singh, R. K. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.17.706416 · Cited by 1
“Although the mechanisms underlying these associations is unclear, Enterococcus peptidoglycan stimulates inflammation 30,31 , which may underlie the inflammatory symptoms characteristic of patients with dybiosis 32 .”
RecT recombinase expression enables efficient gene editing in EnterococcusPreprint
Chen, V., Griffin, M. E., & Hang, H. C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.01.278044
Self-citationRecent pharmacological approaches for the treatment of renal cell carcinoma
Alimohammadi, A., Fajković, H., Mesut Remzi, A., Shariat, S. F., & Schmidinger, M. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2053521
Reproducible stool metagenomic biomarkers linked to the melanoma immunotherapy positive outcomePreprint
Olekhnovich, E. I., Ivanov, A. B., Babkina, A. A., Sokolov, A. A., Игоревич, У. В., Fedorov, D. E., & Ilina, E. N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.01.486538
Treatment with Lactobacillus delbruckii inhibits hypertrophic scar fibrosisPreprint
Wu, G., Shen, K., Han, F., Cheng, J., Han, S., Wang, X., Xin, K., & Hu, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1947931/v1
Tian, D., Cui, M., & Han, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.05.522895
Systemic Onco-Sphere: Host Microbiome and Cancer
Saw, P. E., & Song, E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1183-7_25
Wang, B., Qiu, Y., Xie, M., Huang, P., Yu, Y., Sun, Q., Shangguan, W., Li, W., Zhu, Z., Xue, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3762145/v1
Guillain-Barre in the long-term acute care hospital setting: Ventilation does not prolong stay
Weil, K., Baumann, V., Brown, B., Nadeau, R., Hrdlicka, H. C., Gerstenhaber, B. J., Rosenblum, D. S., & Manning, E. P. (2024) · Journal of Mechanical Ventilation · doi:10.53097/jmv.10094
Choi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · Figshare · doi:10.6084/m9.figshare.24940448
FOCUS on NOD2: Advancing IBD Drug Discovery with a User-Informed Machine Learning Framework
Choudhary, R., & Mahadevan, R. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00148
Fecal Microbiota Transplantation and Cancer Immunotherapy: Current Evidence and Future Directions
Mokhtarpour, K., Akbarzadehmoallemkolaei, M., & Rezaei, N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_419
Wang, J., Fei, B., & Wang, C. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/8242903
Probiotics and Their Immunomodulatory Properties
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_28
Cancer and microbiome-targeted therapies
Meena, A. S., Singh, P., & Shukla, P. K. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2024.12.006 · Cited by 5
Causal associations between gut microbiota and cancersPreprint
Yue, Z., Yan, J., Shen, L., Zhao, C., Yang, X., Yao, Y., Song, D., Xu, C., Bi, C., xiong, Z., et al. (2025) · medRxiv · doi:10.1101/2025.02.17.25322359
Du, Y., Wang, Y., Yang, M., Lin, L., Zhang, J., Huang, Z., Liu, C. X., Liu, S., Ma, J., Yang, C. J., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202503049
Gut microbiota and gastrointestinal tumors: insights from a bibliometric analysis
Chen, C., Wang, X., Han, X., Peng, L., & Zhang, Z. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1558490 · Cited by 1
“Additionally, Enterococcus spp. have been shown to enhance responses to chemotherapy and ICB in mouse melanoma models by secreting SagA, which hydrolyzes bacterial peptidoglycans to create muropeptides that activate NOD2 signaling in macrophages, triggering immune activation (Griffin et al., 2021).”
Characteristics of Gut Microbiota in Inflammatory Bowel Disease and Colorectal Cancer
Song, A. (2025) · BIO Web of Conferences · doi:10.1051/bioconf/202517401004
Righetti, F., Massara, M., & Calcinotto, A. (2025) · The microbiomes of humans, animals, plants, and the environment · doi:10.1007/978-3-031-84065-4_8
Prospect of interdisciplinary research on gut microbiota and colorectal cancer immunotherapy
Lu, Y., Zhang, Z., Chen, L., Xue, P., Zhang, Y., Li, Y., & Guo, H. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104832 · Cited by 1
Li, H., Yang, G., Yang, J., Yin, J., Yao, L., Zhang, Y., Zhu, J., Liao, Y., Liu, Z., & Li, N. (2025) · International Journal of Microbiology · doi:10.1155/ijm/5514372
Wang, B., Qiu, Y., Xie, M., Huang, P., Yu, Y., Sun, Q., Shangguan, W., Li, W., Zhu, Z., Xue, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26170561
Choi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · Figshare · doi:10.6084/m9.figshare.26660545
Choi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · Figshare · doi:10.6084/m9.figshare.24941004
Manipulating gut microbial metabolites for cancer therapy: A metabolism-centric approach
Karne, A. S., Alam, M. I., Tiwari, A., Singh, H., Singh, R. K., & Yadav, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33459-7.00003-x
Identification and Evaluation of Benzimidazole- Agonists of Innate Immune Receptor NOD2
Wittle, L. E., Ocius, K. L., Chordia, M. D., Wagoner, C. M. V., Bullock, T. N. J., & Pires, M. M. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00737
Guo, Y., Zou, S., Yang, X., Li, R., Fu, W., Xu, C., Zhang, F., & Yang, X. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1680593 · Cited by 1
Flow Cytometric Screening Reveals Nucleic Acid Dyes Aberrantly Stain Peptidoglycan Sacculi
Falco, N., Leonard, J. T., Jones, P. M., & Griffin, M. E. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00886
Self-citationmGem: Applying microbiome therapeutic learnings to next-generation agricultural bioproducts
Holmes, E. C. (2026) · mBio · doi:10.1128/mbio.03323-25
Meng, D., Zhou, W., Liang, H., Xu, S., Zhang, Y., Wang, Y., Yang, Y., Zhang, Z., Yao, Y., Ding, Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.17.712240
Abedi, A., Moghaddam, M. M., Kachuei, R., & Fooladi, A. A. I. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01171-5
Marcos-Kovandzic, L. (2024) · theses.fr (ABES) · doi:10.70675/3bde4b45z23ecz4b69zb90dzabccd7cd7fca
Host and gut microbiota crosstalk: A new paradigm for colorectal cancer immunotherapy
Ti, D.-D., Liu, P., Wu, C.-Y., Shi, Z., Guo, S.-M., & Gao, Z. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i4.118606
Sikdar, S., Kim, D., Wang, T., Benaoudia, S., Rajwani, J., Ellestad, K. K., Douglas, P., Filandrová, R., Verhey, T. B., Ellestad, K. I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.23.720410
Deng, Y., Chen, R., Gao, X., Wu, H., He, N., Hu, N., Zhang, W., Chen, L., Zheng, X., & Jiang, J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08170-6
Akram, F., Zainab, S., Shabbir, I., & Haq, I. U. (2026) · Folia Microbiologica · doi:10.1007/s12223-026-01515-0
Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective
Shen, Y., Lu, S.-M., Yang, L., Li, Y., Zhang, Y., & Liang, L. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2026.04.028 · Cited by 1
“For instance, by genetically engineering Enterococcus faecalis , researchers discovered that specific structural modifications of its cell wall peptidoglycan can modulate immune cell activity, thereby enhancing the immune response [73].”
Strokach, A. A., Zakharevich, N. V., Агинова, В. В., Grigoryevskaya, Z., Petukhova, Bagirova, N. S., Romanov, M. V., Dyachkova, M. S., Morozov, M. D., Veselovsky, V. A., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2681788 · Cited by 1
Gut Microbiota–Host Crosstalk: Decoding Mechanisms and Therapeutic Opportunities
Zhang, M. M., Chen, Z. F., Zhao, X., Liu, S., Jiao, P., Guo, Y., Wang, C., Zhang, H., Chen, R., Li, Y. P., et al. (2026) · Engineering · doi:10.1016/j.eng.2026.06.005 · Cited by 2
Fukuhara, M., Sahay, B., Fanger, G. R., & Freguia, C. F. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04480-2 · Cited by 1
“We have previously shown that Lactococcus lactis engineered to express the peptidoglycan hydrolase SagA (R-5780) significantly enhanced the efficacy of anti-PD-L1 therapy, and the observed activity was driven by SagA [10].”
InfluentialSelf-citationSu, X., Xiang, Y., Zhao, H., Li, O., Zhang, L., & Guo, B. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1839030 · Cited by 1
Feng, S., Adamson, C., Li, C., Ng, E. W. L., & Qiao, Y. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535544123 · Cited by 1
Davar, D., Zarour, H. M., & Trinchieri, G. (2026) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-026-00916-y
Chandra, J., Wang, H., Hossain, T., Tillett, B. J., Berman, C., Nissen, M. D., Joseph, S. R., Simpson, F., Walpole, E. T., McCaffrey, E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10134278/v1
Gouveia, L., Serpa, J., & Mendes, C. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_3
Zhang, Y., Wang, S., Chang, S., Li, Y., Dang, Y., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1803970 · Cited by 1
NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer
Wei, X., Yang, L., Wang, Y., Wang, K., Wang, D., Gao, M., Liu, X., Yang, X., Wang, S., Zheng, Y., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02758-6 · Cited by 1
Birla, P., Yang, L., Shan, W., Minamisawa, S., Dhaygude, O., Manoj, H., Lee, A. J., Ferri, J., Zheng, Y., Munoz, A. J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2617943123
Enterococcus and cancer: from mechanistic insights to clinical translation
Feng, H., Huang, X., Zhuang, Y., Pu, L., Dong, R., & Ren, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1882184
“These mechanisms reshape the tumor microenvironment and promote effector T cell expansion, thereby synergistically enhancing the ef fi cacy of chemotherapy and immune checkpoint inhibitors (42, 44).”
Liu, M., Su, X., Huang, X., Yang, X., Chen, Y., Xu, J. M., & He, Y. (2026) · Applied and Environmental Microbiology · doi:10.1128/aem.01133-26
Interplay of gut microbiota, immune cells and natural products in reshaping cancer immunotherapy
Wu, X., Lu, L., Li, T., Zhao, L., Wang, L., Yao, Y., Chen, J., Liu, T., Li, X., Zhu, X., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1898063
Genetic and microbial regulation of NOD2 signaling in homeostasis and disease
Wang, Y., Nie, J., Lin, G., He, X., & Zhou, H. (2026) · MedScience · doi:10.1007/s11684-026-1239-6
Kobayashi, S., Hamaguchi, T., Oishi, R., Tozuka, Y., Fukushima, T., Yamamoto, K., Furuse, J., & Ueno, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1806667
“Among the microbiomes, Ruminococcaceae (15), Bi fi dobacterium (16), and Enterococcus species (17) have been reported to promote the response to ICIs.”
Toll-like Receptor 2 Recognition of Microbiota Lipoproteins and Lipids in Immunity and Therapy
Zhang, X., Dudkina, N., Turner, A. M., & Hang, H. C. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00498 · Cited by 1
Self-citationBacterial metabolic–immune reprogramming in cancer: from living vectors to engineered biofactories
Wu, J., Xu, L., Chen, Q., Yu, L., Liu, Z., & Xia, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115394
Farah, H. S., Padmapriya, G., Sahoo, S., Srivastav, S. K., Khdir, M. M., Rani, A., Axmedova, F., & Бекзод, Б. Э. (2026) · Folia Microbiologica · doi:10.1007/s12223-026-01608-w
Gut bacterial-derived beneficial proteins in intestinal disease
Zhou, S., Tian, Q., Ullah, S., Su, D., Geng, J., & Zhang, M. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128794
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications
Porcari, S., Bolte, L. A., Björk, J. R., Elkrief, A., Derosa, L., Ferrari, M., Pezzullo, A. M., Severino, A., Fusco, W. G., Messaoudene, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.012
Sagawa, T., Hirakawa, M., Nagashima, H., & Fujikawa, K. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01853-9
“Griffin et al. identified the Enterococcus peptidoglycan hydrolase SagA and NOD2-dependent mur-opeptide sensing as experimentally tractable mediators of anti-PD-L1 response [9 ].”
Metadata
- Authors
- Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C.
- Affiliations
- Scripps Research Institute (US)
- Rockefeller University (US)
- Rise Therapeutics, 1405 Research Blvd. Suite 220, Rockville, MD 20850, USA.
- Corresponding author
- Hang, Howard C.
- ORCID
- Venue
- Science
- Published
- 2021-08-27
- Volume
- 373
- Issue
- 6558
- Pages
- 1040-1046
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9503018
- OpenAlex
- W3194929095
- Cited by
- 366
- References
- 75
- Citations by year
- 2026: 69 · 2025: 71 · 2024: 83 · 2023: 80 · 2022: 52 · 2021: 10
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1R01CA245292-01, A1070084)
- Melanoma Research Foundation (Career Development Award)
- ASCRS Research Foundation (HCFR-19-03-02)
- Hope Funds for Cancer Research (HCFR-19-03-02)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- Enterococcus, sagas, peptidoglycan remodeling, cancer immunotherapy, PD-L1 blockade, gut microbiota, muramyl peptides, NOD2 signaling, innate immunity, bacterial cell wall degradation
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Bacterial Proteins, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, N-Acetylmuramoyl-L-alanine Amidase, Peptide Fragments, Peptidoglycan, Enterococcus faecalis, Signal Transduction, Enterococcus, Enterococcus faecium, Probiotics, Mice, Nod2 Signaling Adaptor Protein, Bacterial Load, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.